Adia Nutrition, Inc. (ADIA) has engaged Lucosky Brookman LLP as legal counsel to support a planned uplisting from the OTC Markets to the Nasdaq Capital Market or a similar senior exchange and to advise on a contemplated bridge financing transaction. Under an engagement letter dated August 14, 2026, the firm will handle preparation and filing of a Form S-1 registration statement, related SEC comment responses and amendments, the listing application, and structuring and documentation of the bridge financing, as well as related corporate matters.
Fees for these uplist and bridge financing services are fixed at $150,000, with additional amounts payable if hourly billings exceed 115% of that fee. The fee is scheduled as $30,000 at closing of the bridge financing, $50,000 upon filing the Form S-1, and the balance (plus any excess hourly amounts) at the uplisting closing. After listing on Nasdaq or the New York Stock Exchange, ongoing Exchange Act and related securities work will be billed at $8,000 per month, with other work at stated hourly rates. The firm receives expense reimbursement, customary indemnification, and a security interest in the company’s assets to secure outstanding obligations, and the agreement may be terminated by either party with written notice, subject to payment of amounts due.
Adia Nutrition, Inc. reports a corporate name change to Adia Med, Inc. The company filed a Certificate of Amendment in Nevada on June 2, 2026, changing its legal name and updating its Amended and Restated Articles of Incorporation, with no other changes to articles or bylaws.
Regulatory approval of the name change from FINRA was received on July 10, 2026. Common stock continues to trade on the OTC Markets Venture Market under the ticker “ADIA”, and existing stock certificates remain valid and do not need to be exchanged. Future reports will use the new corporate name Adia Med, Inc.
Adia Nutrition, Inc. focuses on AHSCT medical procedures for multiple sclerosis and biologic products through its Adia Med and Adia Labs segments. For the six months ended June 30, 2026, revenue rose to $661,660, mainly from medical procedures of $434,670 and biologics of $221,525, generating gross profit of $350,157.
The company still recorded a six‑month net loss of $122,107, though it achieved quarterly net income of $40,418 in the three months ended June 30, 2026. The balance sheet shows cash of $128,115, a related‑party line of credit balance of $835,312, an accumulated deficit of $16,095,589, and a stockholders’ deficit of $379,781. Management discloses “substantial doubt” about continuing as a going concern and expects to rely on increasing revenues and a $1,000,000 related‑party credit facility to fund operations.
Adia Nutrition, Inc. reports sharply higher activity but continued losses for the three months ended March 31, 2026. Revenue rose to $176,275, mainly from medical procedures of MS patients and sales of biologics, producing gross profit of $67,577.
The company recorded a net loss of $162,525 and an accumulated deficit of $16,136,007, and its 10-Q states there is “substantial doubt” about its ability to continue as a going concern. Cash was $136,716 with total assets of $776,868 and total liabilities of $1,197,067, including a related-party line of credit of $723,656. As of March 31, 2026, 94,404,696 Class A common shares were outstanding.
ADIA Nutrition, Inc. filed its annual report, detailing a transition from a former shell into an operating regenerative-medicine and biologics business focused on stem-cell therapies and supplements. In 2025, the company generated $700,508 in revenue, mainly from sales of biologics and medical procedures, but recorded a net loss of $395,464 and an accumulated deficit of $15,973,482. Management’s auditors raised substantial doubt about ADIA’s ability to continue as a going concern. ADIA operates FDA-registered perinatal tissue products under Section 361, runs a Winter Park, Florida clinic, and uses a related-party credit line and small equity raises to fund operations while it scales its stem-cell and supplement activities.
Adia Nutrition, Inc. files a Form 10 to register its Common A Stock under the Exchange Act and describe its transition from a dormant shell into an operating regenerative medicine and supplements business. After court-appointed custodianship and several control changes, the company now runs Adia Med clinics and Adia Labs, focusing on autologous stem cell procedures and umbilical cord stem cell biologics such as AdiaVita and AdiaLink, alongside an 18% stake in supplement seller Cement Factory.
Revenue grew to $637,145 for the nine months ended September 30, 2025, mainly from biologic product sales and medical procedures, but the company still recorded a net loss and has an accumulated deficit over $15 million, leading auditors to raise substantial doubt about its ability to continue as a going concern. Operations depend heavily on a related-party credit line, a third‑party lab, and navigating complex FDA and AATB rules for human tissue products. The filing also highlights significant regulatory, competitive, liquidity and penny‑stock risks, as well as concentrated voting control through a single preferred share class.